Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Canada Graduate Scholarships-Master?s Program Application

FY 2019-20

Summary
"Background:. In Type 1 Diabetes (T1D), the insulin producing beta cells are destroyed by the patient's own immune cells, rendering them unable to regulate blood glucose. Regulatory T cells (Tregs) normally prevent this autoimmune attack, but T1D patients are thought to have dysfunctional Tregs. Mouse models have shown polyclonal Tregs can delay and reverse diabetes, but giving large numbers of non-specific Tregs risks immune suppression. Therefore, a more efficient system would be to infuse Tregs that can specifically prevent beta cell attack. However, naturally-occurring, specific Tregs in blood are rare and so it is difficult to isolate and expand them for infusion. Objectives:. My project aims to engineer specific Tregs by utilizing Chimeric Antigen Receptors (CARs). CARs are derived from high affinity antibodies and when expressed on the cell surface can re-direct T cell specificity. I aim to create CAR-Tregs to use as a therapy for T1D. Aim 1: Generate and validate CARs specific for molecules relevant to T1D. Aim 2: Generate T1D-relevant CAR-Tregs and test their function in vitro. Aim 3: Test if infusion of CAR-Tregs into T1D-prone mice can delay diabetes progression. Methods:. 1. Use molecular biology methods to clone and express new T1D-relevant CARs and flow cytometry to test for their specificity. 2. Use retrovirus to genetically modify Tregs so they express CARs, then cellular immunology assays to test CAR-stimulated proliferation and suppression. Both relevant and irrelevant CAR stimuli will be tested to determine whether activation and suppression occurs in an antigen dependent manner. 3. Infusion of CAR-Tregs into mice using a diabetic mouse model. The mice will be injected with CAR-Tregs and blood glucose will be monitored over several weeks. "
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428798
Name
Fung Vivian
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Canada Graduate Scholarships-Master?s Program Application
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antigen Specificity; Chimeric Antigen Receptors; Immunomodulation; Immunotherapy; Mouse Models; Regulatory T Cells; Type 1 Diabetes
Abstract
"Background:. In Type 1 Diabetes (T1D), the insulin producing beta cells are destroyed by the patient's own immune cells, rendering them unable to regulate blood glucose. Regulatory T cells (Tregs) normally prevent this autoimmune attack, but T1D patients are thought to have dysfunctional Tregs. Mouse models have shown polyclonal Tregs can delay and reverse diabetes, but giving large numbers of non-specific Tregs risks immune suppression. Therefore, a more efficient system would be to infuse Tregs that can specifically prevent beta cell attack. However, naturally-occurring, specific Tregs in blood are rare and so it is difficult to isolate and expand them for infusion. Objectives:. My project aims to engineer specific Tregs by utilizing Chimeric Antigen Receptors (CARs). CARs are derived from high affinity antibodies and when expressed on the cell surface can re-direct T cell specificity. I aim to create CAR-Tregs to use as a therapy for T1D. Aim 1: Generate and validate CARs specific for molecules relevant to T1D. Aim 2: Generate T1D-relevant CAR-Tregs and test their function <em>in vitro</em>. Aim 3: Test if infusion of CAR-Tregs into T1D-prone mice can delay diabetes progression. Methods:. 1. Use molecular biology methods to clone and express new T1D-relevant CARs and flow cytometry to test for their specificity. 2. Use retrovirus to genetically modify Tregs so they express CARs, then cellular immunology assays to test CAR-stimulated proliferation and suppression. Both relevant and irrelevant CAR stimuli will be tested to determine whether activation and suppression occurs in an antigen dependent manner. 3. Infusion of CAR-Tregs into mice using a diabetic mouse model. The mice will be injected with CAR-Tregs and blood glucose will be monitored over several weeks. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fung, Vivian
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~